Breaking News Instant updates and real-time market news.

HAIN

Hain Celestial

$36.36

0.46 (1.28%)

, SNAP

Snap

$14.06

(0.00%)

09:40
02/07/18
02/07
09:40
02/07/18
09:40

Unusually active option classes on open February 7th

Unusual total active option classes on open include: Hain Celestial (HAIN), Snap Inc. (SNAP), FXI (FXI), Wynn Resorts (WYNN), RIOT (RIOT), Disney (DIS), Gilead (GILD), Petrobras (PBR), and Chesapeake (CHK).

HAIN

Hain Celestial

$36.36

0.46 (1.28%)

SNAP

Snap

$14.06

(0.00%)

FXI

iShares China Large-Cap ETF

$50.77

(0.00%)

WYNN

Wynn Resorts

$163.22

-2.26 (-1.37%)

RIOT

Riot Blockchain

$12.95

2.25 (21.03%)

DIS

Disney

$106.17

(0.00%)

GILD

Gilead

$80.38

2.01 (2.56%)

PBR

Petrobras

$13.33

(0.00%)

CHK

Chesapeake

$3.13

(0.00%)

  • 07

    Feb

  • 07

    Feb

  • 11

    Feb

  • 12

    Feb

  • 19

    Feb

  • 22

    Feb

  • 23

    Feb

  • 01

    Mar

  • 07

    Mar

HAIN Hain Celestial
$36.36

0.46 (1.28%)

12/22/17
LOOP
12/22/17
NO CHANGE
Target $38
LOOP
Hold
Hain unlikely to receive premium in a takeover, says Loop Capital
Following the acquisitions of Amplify Snack Brands (BETR) and Snyder's-Lance (LNCE), Loop Capital analyst Andrew Wolf revisited his outlook for Hain Celestial Group (HAIN) as an acquisition candidate. The analyst's sum-of-the-parts valuation range for the company remains at $42 to $56 per share, representing a premium range of 1% to 35% to the current share price. Hain, however, is not likely to receive much of a premium valuation in a takeout because its core domestic business is barely growing, in contrast to the companies that have been acquired, Wolf tells investors in a research note. He keeps a Hold rating on the stock with a $38 price target.
11/10/17
LOOP
11/10/17
NO CHANGE
Target $38
LOOP
Hold
Hain Celestial price target lowered to $38 from $44 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target for Hain Celestial Group to $38 citing uncertainty in the cost and timing of a turnaround at the company's U.S. segment. The analyst keeps a Hold rating on the shares.
11/21/17
WELS
11/21/17
NO CHANGE
WELS
Nestle acquisition of Hain makes sense, says Wells Fargo
Wells Fargo analyst John Baumgartner believes a Nestle (NSRGY) acquisition of Hain Celestial (HAIN) would make sense. Bloomberg last night reported that Nestle is among the companies exploring a purchase of Hain. Nestle would likely be a good fit for Hain's baby food, skin care and tea businesses, Baumgartner told investors earlier in a research note. The analyst sees "tax leakage" as a headwind for any deal and keeps a Market Perform rating on Hain with a $38 price target.
12/19/17
MAXM
12/19/17
NO CHANGE
MAXM
Buy
Hain Celestial could be attractive target for CPG manufacturers, says Maxim
Maxim notes that it has observed consolidation in the consumer-packaged goods industry over the past three months, particularly in the area of healthy snacking. Seeing Hain Celestial as a leading producer of better-for-you snacks, the firm believes the company could be an attractive acquisition target for consumer-packaged goods manufacturers seeking to take advantage of the health and wellness trend within snack foods. Based on Maxim's analysis of comparable transactions, it thinks the starting point for a potential acquisition of Hain would be $55-$60 per share.
SNAP Snap
$14.06

(0.00%)

02/07/18
MSCO
02/07/18
NO CHANGE
Target $11
MSCO
Underweight
Snap's 'next story' still uncertain, says Morgan Stanley
Morgan Stanley analyst Brian Nowak noted that Snap's Q4 results were better than expected, but he thinks the durability of the momentum into 2018 is less certain. The analyst, who still sees challenges and uncertainties as Snap works to turn its platform around, only increased his 2018 and 2019 revenue estimates by 3% each following the Q4 report. Nowak edged up his price target on Snap to $11 from $10 and keeps an Underweight rating on the stock, which has been upgraded by at least six other firms this morning.
02/07/18
LEHM
02/07/18
NO CHANGE
Target $21
LEHM
Overweight
Barclays gives Snap its first 'Gatorade shower,' ups price target to $21
Barclays analyst Ross Sandler raised his price target for Snap to $21 from $18 saying the company last night reported daily active users and revenue that were 4M and 13% above consensus. In a post-earnings research note titled "SNAP Takes Its First Gatorade Shower," Sandler adds that the tone of the conference call was upbeat. He reiterates his belief that the worst is behind Snap and thinks the stock can "grind higher" despite today's 21% rally. The stock in premarket trading is up $2.89 to $16.95. Ross keeps an Overweight rating on the name.
02/07/18
OPCO
02/07/18
NO CHANGE
Target $19
OPCO
Outperform
Snap price target raised to $19 from $14 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Snap to $19 from $14 after the company reported significantly better than expected Q4 revenue and user growth. The analyst reiterates an Outperform rating on the shares.
02/07/18
ADAM
02/07/18
NO CHANGE
Target $16
ADAM
Hold
Snap made progress on product redesign and user growth, says Canaccord
Canaccord analyst Michael Graham said Snap's Q4 results were generally solid, as the company made progress on product redesign and daily active user growth. They also made progress on its advertising platform, but the analyst said the key for 2018 will be to see its density build. Graham maintained his Hold rating and raised his price target to $16 from $12 on Snap shares.
FXI iShares China Large-Cap ETF
$50.77

(0.00%)

WYNN Wynn Resorts
$163.22

-2.26 (-1.37%)

02/07/18
ROTH
02/07/18
DOWNGRADE
Target $170
ROTH
Neutral
Roth says Wynn Resorts removing 'a visionary, not an overhang,' cuts to Neutral
As previously reported, Roth Capital analyst David Bain downgraded Wynn Resorts to Neutral from Buy following the news of Steve Wynn stepping down as Chairman and CEO. The analyst believes Wynn's resignation is unlikely to shift investor discussions to fundamentals. Instead, he believes it raises additional questions on potential risks and simultaneously "removes one of, if not the greatest hospitality leaders and visionaries" from a company he created and "actively and intimately molds on a daily basis." Bain lowered his price target on Wynn shares to $170 from $210.
02/07/18
NOMU
02/07/18
UPGRADE
NOMU
Buy
Wynn Resorts upgraded to Buy from Neutral at Nomura Instinet
02/07/18
NOMU
02/07/18
UPGRADE
Target $211
NOMU
Buy
Wynn Resorts upgraded to Buy from Neutral at Nomura Instinet
Nomura Instinet analyst Harry Curtis upgraded Wynn Resorts to Buy and raised his price target for the shares to $211 from $175. The risk is that Wynn loses any gaming licenses is lower following the resignation of Steve Wynn, Curtis tells investors in a research note. He also believes the company is now a breakup/acquisition target.
02/07/18
ROTH
02/07/18
DOWNGRADE
ROTH
Neutral
Wynn Resorts downgraded to Neutral from Buy at Roth Capital
RIOT Riot Blockchain
$12.95

2.25 (21.03%)

DIS Disney
$106.17

(0.00%)

01/24/18
ARGS
01/24/18
NO CHANGE
ARGS
Hold
Netflix valuation 'significantly above peers', says Argus
Argus analyst Joseph Bonner keeps his Hold rating on Netflix while raising his FY18 EPS estimated to $2.73 from $2.01 after the company's latest earnings report. Bonner warns however that while Netflix subscription count is benefiting from a "secular growth of internet-delivered on-demand video", the company is also taking on more debt and burning through cash while attracting a host of competitors that include its own suppliers - Time Warner (TWX), Disney (DIS), and HBO - along with "deep-pocketed" rivals AT&T (T), Amazon (AMZN), Facebook (FB), and Google (GOOGL). The analyst adds that the valuation metrics on Netflix are also significantly higher than peers at a trailing EV/EBITDA multiple of 124-times - well above both the peer average of 29-times and Amazon's 50-times.
01/28/18
PIPR
01/28/18
NO CHANGE
PIPR
Growth of sports rights may be coming down, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says he is starting to see some evidence that the growth of sports rights may be coming down toward a more reasonable rate. The analyst notes that only CBS (CBS), Fox (FOXA) and NBC (CMCSK; CMCSA) submitted bids for Thursday Night Football rights, with CBS and NBC submitting bids below their current rate of $450M per year, and Fox making a higher bid for the rights, in a likely effort to establish itself as a "live sports and news" network in the wake of selling a majority of assets to Disney (DIS). On the digital side, Facebook (FB) declined to make an offer for digital streaming rights to TNF, while Amazon (AMZN), which paid $50M this year, and Twitter (TWTR), which paid $10M last year did submit bids.
02/07/18
RILY
02/07/18
NO CHANGE
Target $125
RILY
Neutral
Disney price target raised to $125 from $122 at B. Riley FBR
B. Riley FBR analyst Barton Crockett raised his price target for Disney to $125 citing an improved mix shift to theme parks following last night's results. He believes this deserves a higher multiple but keeps a Neutral rating on Disney shares.
02/07/18
MSCO
02/07/18
NO CHANGE
Target $130
MSCO
Overweight
Disney risks stabilizing while OTT opportunity grows, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne noted that ESPN sub losses were stable to slightly better than the prior quarter for a second quarter in a row, while the emergence of Virtual Multichannel Video Programming Distributors and the benefit of renewals set the network up for improved results even before the benefit of the direct-to-consumer app. While the impact of lost third-party licensing as a result of a pivot to over-the-top won't be clear for a while, Swinburne thinks leaning towards OTT is likely the right strategic move, he added. He maintains an Overweight rating on Disney with a $130 price target.
GILD Gilead
$80.38

2.01 (2.56%)

02/07/18
SBSH
02/07/18
NO CHANGE
Target $105
SBSH
Buy
Gilead should be bought ahead of pipeline catalysts, says Citi
Citi analyst Robyn Karnauskas raised her price target for Gilead Sciences to $105 from $103 following last night's Q4 results. The analyst recommends buying the stock ahead of pipeline catalysts and keeps a Buy rating on the name. The base business seems to be stabilizing while gene therapy could be a potential growth area, Karnauskas tells investors in a post-earnings research note.
01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
01/30/18
01/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CVS Health (CVS) upgraded to Strong Buy from Buy at Needham by analyst Kevin Caliendo, who contended that the stock remains underowned and, unlike its peers, yet to rally beyond the expectations of benefits from the tax changes. The analyst says the company's multiple has remained constant despite the expansion in the rest of the pharma services industry, forecasting EPS growth of 8%-10% beyond the modeled $8 per share in 2019. 2. JetBlue (JBLU) upgraded to Overweight from Neutral at JPMorgan by analyst Jamie Bakier who said the company's costs are "gradually coming under control" and its balance sheet is "sound." The analyst also upgraded United Continental (UAL) to Overweight from Underweight, saying the shares are the "cheapest in the sector and among the most washed out, having declined the most from recent highs." 3. Gilead (GILD) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who said that tax reform could lower the company's tax rate to 22% in 2018 versus prior estimates of 28%. The analyst also raised her nonalcoholic steatohepatitis and JAK-1 probability of success estimates to 50% with both Phase 3 trials expected in the next 12 months. Further, Karnauskas expects Gilead's hepatitis C virus business to stabilize by mid-2018. 4. Intel (INTC) upgraded to Buy from Neutral at Citi by analyst Christopher Danely, who said overly conservative guidance and poor sentiment from years of underperformance should drive estimates and the stock higher in the near term. He believes management's "new habit" of conservative guidance is good for the stock. 5. Albemarle (ALB) upgraded to Buy from Neutral at UBS by analyst John Roberts, who said the stock is down 23% from the November high despite no change to the outlook for lithium. The analyst attributes the pullback to larger scale lithium expansion announcements and raising concerns of potential oversupply. He believes the market is pricing in 10% annual realized price declines for Albemarle over the next few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/30/18
SBSH
01/30/18
UPGRADE
Target $103
SBSH
Buy
Citi upgrades Gilead to Buy with $103 target following tax reform
Citi analyst Robyn Karnauskas upgraded Gilead Sciences to Buy from Neutral and raised her price target for the shares to $103 from $81. The drugmaker closed yesterday up $3.34 to $88.80. Tax reform could lower the company's tax rate to 22% in 2018 versus prior estimates of 28%, Karnauskas tells investors in a research note. The analyst also raised her nonalcoholic steatohepatitis and JAK-1 probability of success estimates to 50% with both Phase 3 trials expected in the next 12 months. Further, Karnauskas expects Gilead's hepatitis C virus business to stabilize by mid-2018.
PBR Petrobras
$13.33

(0.00%)

10/18/17
SOCG
10/18/17
DOWNGRADE
SOCG
Hold
Petrobras downgraded to Hold from Buy at Societe Generale
Societe Generale analyst John Herrlin downgraded Petrobras to Hold from Buy citing valuation and maintained a $10.50 price target.
01/23/18
HSBC
01/23/18
DOWNGRADE
HSBC
Hold
Petrobras downgraded to Hold from Buy at HSBC
02/01/18
GSCO
02/01/18
UPGRADE
GSCO
Neutral
Petrobras upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Bruno Pascon upgraded Petrobras to Neutral after his firm raised its oil price assumptions for 2018-2020. The analyst also upgraded his view on the Latin America Energy sector to Neutral.
09/01/17
DBAB
09/01/17
UPGRADE
DBAB
Hold
Petrobras upgraded to Hold from Sell at Deutsche Bank
CHK Chesapeake
$3.13

(0.00%)

01/16/18
MZHO
01/16/18
DOWNGRADE
MZHO
Underperform
Chesapeake downgraded to Underperform from Neutral at Mizuho
12/11/17
FBCO
12/11/17
INITIATION
FBCO
Underperform
Chesapeake initiated with an Underperform at Credit Suisse
Credit Suisse analyst William Featherston initiated Chesapeake with an Underperform rating and $3 price target.
10/09/17
JEFF
10/09/17
DOWNGRADE
JEFF
Underperform
Chesapeake downgraded to Underperform from Hold at Jefferies
Jefferies analyst Mark Lear downgraded Chesapeake to Underperform from Hold with a $2 price target, saying that while Chesapeake has made great strides in simplifying its corporate structure and asset base, the company still has a high fixed cost burden and a comparatively weak inventory of high return drilling inventory, and Lear sees "more value in operators with larger, core positions in higher value plays."
10/09/17
JEFF
10/09/17
DOWNGRADE
JEFF
Underperform
Chesapeake downgraded to Underperform from Hold at Jefferies

TODAY'S FREE FLY STORIES

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

, PCG

PG&E

$42.98

2.44 (6.02%)

18:17
06/22/18
06/22
18:17
06/22/18
18:17
Hot Stocks
Northwest Natural to sell Gill Ranch Storage to SENSA Holdings »

NW Natural (NWN)…

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

PCG

PG&E

$42.98

2.44 (6.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ORLY

O'Reilly Automotive

$285.90

-1.18 (-0.41%)

18:03
06/22/18
06/22
18:03
06/22/18
18:03
Hot Stocks
O'Reilly Automotive's O'Reilly sells 19,250 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$33.15

0.02 (0.06%)

17:46
06/22/18
06/22
17:46
06/22/18
17:46
Hot Stocks
South Jersey Industries announces approval of Elizabethtown Gas purchase »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAAS

AquaVenture

$15.36

0.12 (0.79%)

17:27
06/22/18
06/22
17:27
06/22/18
17:27
Hot Stocks
AquaVenture extends long-stop date for Ghana plant acquisition to September 30 »

AquaVenture announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Periodicals
Nissan chooses Thailand for hybrid's first export market, Nikkei reports »

Nissan has planned to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.81

-0.0068 (-0.83%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Hot Stocks
Trovagene CEO William Welch resigns, Dr. Thomas Adams named interim CEO »

Trovagene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$3.26

0.005 (0.15%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.49

-0.15 (-0.45%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Hot Stocks
Aecom to compete for $148.5M U.S. Army contract »

AECOM-Baker JV, Bryan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:17
06/22/18
06/22
17:17
06/22/18
17:17
Hot Stocks
Lockheed Martin awarded $175.3M U.S. Navy contract modification »

Lockheed Martin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:16
06/22/18
06/22
17:16
06/22/18
17:16
Hot Stocks
Lockheed Martin awarded $1.12B U.S. Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

, XLU

Utilities SPDR

$50.75

0.36 (0.71%)

17:14
06/22/18
06/22
17:14
06/22/18
17:14
General news
Week ending ETF Scorecard: Utilities and Real Estate advance, Industrials slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

XLU

Utilities SPDR

$50.75

0.36 (0.71%)

IYR

DJ US Real Estate Index Fund

$80.69

0.56 (0.70%)

XLP

Consumer Staples Sector SPDR

$51.62

0.42 (0.82%)

XLY

Consumer Discretionary Sector SPDR

$111.34

-0.15 (-0.13%)

XLB

S&P Select Materials SPDR

$58.49

0.79 (1.37%)

XLF

Financial Select Sector

$27.07

-0.145 (-0.53%)

XLV

Health Care Select Sector SPDR

$84.91

0.35 (0.41%)

XLK

Technology Select Sector SPDR

$70.78

-0.24 (-0.34%)

XLI

Industrial Select Sector SPDR

$72.59

0.22 (0.30%)

GLD

SPDR Gold Trust

$120.33

0.27 (0.22%)

SLV

iShares Silver Trust

$15.49

0.135 (0.88%)

USO

United States Oil Fund

$14.02

0.71 (5.33%)

UNG

United States Natural Gas Fund

$23.87

-0.24 (-1.00%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.91

-0.015 (-0.02%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$113.99

0.105 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.57

0.06 (0.05%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.11

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.30

0.005 (0.01%)

IWD

iShares Russell 1000 Value

$122.51

0.56 (0.46%)

IWF

iShares Russell 1000 Growth

$146.24

-0.2 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$5.43

0.14 (2.65%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Hot Stocks
Pfenex set to join Russell 2000 Index »

Pfenex announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXE

Bellatrix Exploration

$1.00

-0.0101 (-1.00%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Syndicate
Breaking Syndicate news story on Bellatrix Exploration »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$44.24

0.25 (0.57%)

16:56
06/22/18
06/22
16:56
06/22/18
16:56
Initiation
Logitech initiated  »

Logitech initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.35

0.925 (3.14%)

16:51
06/22/18
06/22
16:51
06/22/18
16:51
Hot Stocks
Breaking Hot Stocks news story on PagSeguro Digital »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

APLS

Apellis

$21.75

-0.2 (-0.91%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Conference/Events
Apellis to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Periodicals
SEC investigates whether companies rounded up earnings, WSJ reports »

The U.S. Securites and…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THRM

Gentherm

$38.20

-0.75 (-1.93%)

16:45
06/22/18
06/22
16:45
06/22/18
16:45
Conference/Events
Gentherm to hold a strategic update »

Strategic Update for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTX

MeiraGTx

$11.86

-0.97 (-7.56%)

16:43
06/22/18
06/22
16:43
06/22/18
16:43
Hot Stocks
Breaking Hot Stocks news story on MeiraGTx »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.80

0.51 (0.59%)

16:39
06/22/18
06/22
16:39
06/22/18
16:39
Conference/Events
Medtronic to hold an analyst and investor briefing »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

, FOX

21st Century Fox

$48.28

0.31 (0.65%)

16:35
06/22/18
06/22
16:35
06/22/18
16:35
Hot Stocks
21st Century Fox extends CFO John Nallen's employment contract to 2021 »

On June 22, 21st Century…

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

FOX

21st Century Fox

$48.28

0.31 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$10.97

0.5 (4.78%)

16:34
06/22/18
06/22
16:34
06/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Fennec »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBBP

Strongbridge Biopharma

$6.20

-0.15 (-2.36%)

16:33
06/22/18
06/22
16:33
06/22/18
16:33
Hot Stocks
Breaking Hot Stocks news story on Strongbridge Biopharma »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

16:30
06/22/18
06/22
16:30
06/22/18
16:30
Options
Preliminary option volume of 16.8M today »

Preliminary option volume…

COOL

PolarityTE

$38.91

-0.09 (-0.23%)

16:28
06/22/18
06/22
16:28
06/22/18
16:28
Conference/Events
PolarityTE to hold a meeting »

Management hosts a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.